Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand to Present at Barclays 26th Annual Global Healthcare Conference
Ligand Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Ligand Partner Eisai Receives Approval for Injection Formulation of Fycompa
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results
Ligand Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)